| Document |
Document Title |
|
WO/2023/183247A2 |
The present invention provides for methods of treating biogenic amine related conditions. Further provided are methods of detecting biogenic amine related conditions, and selection of treatment for patients in need thereof.
|
|
WO/2023/183936A2 |
The present invention provides methods, compositions, and combinations for treating cancer via combined use of a compound that forms a covalent bond with a kinase or pseudokinase, or a pharmaceutically acceptable salt thereof, and at lea...
|
|
WO/2023/178964A1 |
The present invention relates to a method for promoting a drug molecule to reach an action target in a tumor cell, a method for promoting delivery of an endogenous tumor antigen and tumor DNA to a DC, a method for activating a STING path...
|
|
WO/2023/178199A2 |
The present disclosure provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In another aspect, the present disclosure provides bifunctional compounds that can...
|
|
WO/2023/178240A2 |
Provided herein are novel therapeutic applications of Pyk2 (PTK2B) inhibitors to treat low bone mineral density and/or osteoporosis and to treat, prevent, or delay the progression of neurodegenerative disorders such as Alzheimer's disease.
|
|
WO/2023/176872A1 |
Provided is a pharmaceutical composition to be used for radiotherapy that comprises a compound represented by formula (I) [wherein: R1 is an aryl group substituted by a substituent selected from an iodine atom, etc., wherein the aryl gro...
|
|
WO/2023/177560A2 |
The invention provides novel triplet-triplet annihilation upconversion nanoparticles as background free self-standing biological sensors, and devices and methods thereof.
|
|
WO/2023/173824A1 |
Disclosed in the present invention are a hydrophobic methylene blue fluorescent dye, and a preparation method therefor and the use thereof. The hydrophobic methylene blue fluorescent dye has a structural formula as shown in formula (I), ...
|
|
WO/2023/177841A2 |
A method is provided for reducing concurrent use of stimulant medications and alcohol. In an example, the method comprises administering to the subject a combination product that includes an effective amount of one or more stimulant medi...
|
|
WO/2023/178179A2 |
Described herein is a bi-functional compound for removing macrophage migration inhibitory factor (MIF) or immunoglubin G (IgG). Further described herein is a pharmaceutical composition which comprise these bi-functional compounds. Furthe...
|
|
WO/2023/178331A2 |
An anti-tumor agent is provided to a patient to increase a susceptibility of a tumor within the patient to harmonic excitation. Ultrasonic transducers of a wearable are driven to direct a therapeutic ultrasound signal into tissue of the ...
|
|
WO/2023/173131A2 |
The disclosure relates to the use of phosphodiesterase 1 (PDE1) inhibitors alone or in combination with immune checkpoint inhibitor therapies for the treatment of breast cancer, including for promoting antitumor immunity and mitigating t...
|
|
WO/2023/173036A2 |
The present disclosure relates to the use of MASP-2 inhibitors and/or MASP-3 inhibitors and compositions comprising the same for treatment of sickle cell disease, including treatment, reduction, and/or prevention of sickle cell disease s...
|
|
WO/2023/172444A2 |
This document relates to methods and materials for assessing and/or using one or more senotherapeutic agents. In some cases, methods and materials for determining the efficacy of an anti-senescence treatment in a mammal (e.g., a human) a...
|
|
WO/2023/173055A2 |
Provided herein are compositions and methods of using a Mu opioid receptor (MOR) antagonist (e.g. axelopran) alone or in combination with checkpoint inhibitor (such as e.g. an inhibitor of the PD-1/PD-L1 pathway (e.g. an antibody such e....
|
|
WO/2023/172594A2 |
The invention provides methods for treating conditions of immune disfunction, such as rheumatoid arthritis (RA), using enzyme- and substrate-selective exosite inhibitors of A disintegrin and metalloprotease 10 (ADAM10), such as N-(3-chlo...
|
|
WO/2023/172501A2 |
The technology relates in part to methods of selecting for and/or treating subjects having cancer, where the subjects are identified as having at least one genetic structural variant that renders them suitable candidates for a treatment ...
|
|
WO/2023/172669A2 |
The invention is directed to compositions and methods of inhibiting lipogenesis lipid supplies from internal and external sources in a subject. In some embodiments, the invention is directed to compositions and methods for treating cance...
|
|
WO/2023/169546A1 |
The use of an NIR-II photothermal material in preparation of a drug for reversing multidrug resistance of cancer cells. The NIR-II photothermal material is a small organic molecule fluorophore and has near-infrared-II fluorescence emissi...
|
|
WO/2023/173021A2 |
Provided herein are methods for treating acute alcohol toxicity using an agonist for a Fibroblast Growth Factor Receptor (FGFR) and β-Klotho complex such as Fibroblast Growth Factor 21 (FGF21). Also provided are compositions and kits co...
|
|
WO/2023/172913A2 |
Microscaled proteogenomics was deployed to probe the molecular basis for differential response to neoadjuvant carboplatin & taxotere combination chemotherapy for triple-negative breast cancer (TNBC). Proteomic analyses of pre-treatment b...
|
|
WO/2023/173004A2 |
Described are compositions and methods for increasing opioid therapy efficacy and ameliorating opioid use disorder. The compositions and methods target Ptchd1 or neuronal cholesterol.
|
|
WO/2023/172701A2 |
Disclosed are therapeutic combinations for eliciting an entactogenic mindstate, such as through use of compositions comprising imidazoline receptor agents, cannabinoid receptor agents, and/or serotonin receptor agents. Also disclosed are...
|
|
WO/2023/172872A2 |
Disclosed herein include methods, compositions, and kits suitable for use in treating a subject having cancer and/or determining the efficacy of treatment to a subject having a cancer. In some embodiments, the method comprises determinin...
|
|
WO/2023/172855A2 |
The present invention relates to a use of a composition for the manufacture of a drug for treating symptoms of a disease associated with an infection caused by hepatitis B virus (HBV), in particular a chronic HBV infection, in which the ...
|
|
WO/2023/172441A2 |
The present disclosure provides compositions and methods comprising TRPV4 inhibitors for treating respiratory viral infections, inflammatory diseases, and/or respiratory inflammation.
|
|
WO/2023/172718A1 |
Provided herein is technology relating to compositions containing bioactive non-methylene interrupted fatty acids (NMIFAs) for use in improving skin barrier function and related diseases and disorders.
|
|
WO/2023/166209A1 |
The invention relates to a pouch system (1) for the treatment of a biological fluid by electromagnetic irradiation, said pouch system comprising at least one element consisting of an irradiation pouch (2) intended to contain the biologic...
|
|
WO/2023/165052A1 |
Provided is a directionally driven hemostatic microsphere with a puncture function, which comprises hollow pollen and a power system assembled on the surface of the hollow pollen, wherein the surface of the hemostatic microsphere is need...
|
|
WO/2023/168053A2 |
Various methods of treating cancer, autoimmune disease, or any disease involving cellular proliferation are presented herein comprising administering an effective amount of an HPDL inhibitor to the subject. The HPDL inhibitors used herei...
|
|
WO/2023/167842A2 |
Patients with relapsing or refractory cancer have limited treatment options because the knowledge or presence of tumor-associated antigens is lacking. The proposed therapy mounts an antigen-independent anticancer response in a rapid, saf...
|
|
WO/2023/166214A1 |
The invention relates to a pouch system (1) for treating a biological fluid by electromagnetic irradiation, the pouch system comprising at least one element consisting of an irradiation pouch (2) intended to contain the biological fluid ...
|
|
WO/2023/167364A1 |
The present invention relates to: a photosensitive hydrogel for cancer treatment; a photothermal composition comprising the hydrogel as an active ingredient; and a preparation method for a photosensitive hydrogel for cancer treatment. Th...
|
|
WO/2023/159676A1 |
The present invention relates to a polyethylene glycol modified zwitterionic fluorescent probe. A core luminous group of the fluorescent probe of the present invention is a heptamethine chain which is connected to a phenoxy bridge and is...
|
|
WO/2023/163553A1 |
The present invention relates to a compound bearing a photosensitizer and an imidazopyridine derivative, a liposome including the compound, and a photodynamic therapeutic composition containing the compound or liposome. According to exem...
|
|
WO/2023/159234A2 |
Methods and compositions for modulating, e.g., damping, contractile oscillations by targeting and/or mimicking MyBP-C in heart and skeletal muscles, including therapeutics (e.g., small molecules, peptides, enzymes, antibodies, oligonucle...
|
|
WO/2023/159186A2 |
The present disclosure is directed a medical device applied as patch to a wound to promote healing. Engineered cells are disposed in the device that can secrete wound healing factors in response to light utilizing optogenetics. Biomateri...
|
|
WO/2023/159152A2 |
The present disclosure provides herein monotherapies of a LILRB antagonist (e.g., an anti-LILRB2 antibody or anti-LILRB4 antibody) and combination therapies of the LILRB antagonist (e.g., an anti-LILRB2 antibody or anti-LILRB4 antibody) ...
|
|
WO/2023/159182A1 |
Provided herein are anti-Programmed Death-Ligand (PD-L1) antibodies, antigen-binding fragments thereof, multispecific antibodies and encoding polynucleotides. Also provided are PD-L1-targeted phthalocyanine dye conjugates, compositions a...
|
|
WO/2023/156321A1 |
This disclosure relates to therapies in which an antibody drug conjugate is administered together with a composition comprising nanoscale cavitation initiators. Application of ultrasound following administration provides effective, targe...
|
|
WO/2023/159253A2 |
Provided are methods and compositions for treating and/or preventing C. difficile infections, particularly recurring C. difficile infections. The compositions for use in treating and/or preventing C. difficile infections include in some ...
|
|
WO/2023/159048A2 |
Methods of using the small molecule STAT3 inhibitor LLL12B in the treatment of cancer, such as triple-negative breast cancer (TNBC) and pancreatic cancer, either alone or in combination with additional therapeutic agents, such as PARP in...
|
|
WO/2023/159218A2 |
A human patient-derived organoid derived from human pituitary neuroendocrine tumor and methods of preparing the same are disclosed. Drug screening platform to identify compounds or biologics for treatment of Cushing's disease (CD) patien...
|
|
WO/2023/150892A1 |
This application relates to lipid nanoparticles, which include: a helper lipid and an ionizable lipid, at least one lipid layer surrounding an interior having at least one aqeous portion, an encapsulated inorganic particle, and an agent ...
|
|
WO/2023/154959A2 |
A method of treating a subject having a tumor that is susceptible to treatment by CTLA-4 blockade, comprising administering a CTLA-4 inhibitor to the subject, in which the tumor is susceptible to treatment by CTLA-4 blockade when the tum...
|
|
WO/2023/154850A2 |
Fragile X Mental Retardation protein (FMRP) is an RNA-binding protein (RBP) that controls translation of select mRNAs. We discovered that endoplasmic reticulum (ER) stress induces phosphorylation of FMRP on a site that is known to enhanc...
|
|
WO/2023/154349A2 |
The present disclosure is directed to methods of genetically subtyping peripheral t-cell lymphoma.
|
|
WO/2023/154916A2 |
Compositions, methods, and processes for making and using polypeptides, peptides and antibodies for treating a subject in need of therapy for pathogen-induced infection and non-pathogen-induced (organ fibrosis, COPD and asthma), symptom,...
|
|
WO/2023/154494A2 |
Provided herein are compositions and methods of modulating myeloid cell-mediated killing of cancer cells and modulating the activity of myeloid cell immune checkpoint inhibitors. Also provided herein are methods of screening for modulato...
|
|
WO/2023/154450A2 |
A pharmaceutical composition comprising the following components: (i) a positive allosteric modulator (PAM) of the AMPA receptor (e.g., an ampakine or biarylpropylsulfonamide); and (ii) an NMDA receptor antagonist, such as ketamine or an...
|
